Company
Synergy of tradition and modernity for innovative products
Since its foundation more than 50 years ago, Fette Pharma has focused on health and well-being as an essential human good. Originally founded as a medium-sized family business for natural remedies, Fette Pharma today combines tradition and modernity to create innovative product specialties.
Fette Pharma aims to offer medical cannabis also in Germany for a promising treatment and care of patients as well as in the form of a practice-oriented selection of individually tunable therapy options.
With the Israeli company Cannbit, Fette Pharma has a partner at its side that is playing a pioneering role in the era of modern medical cannabis.
Find out more
RE:CANNIS – The new standard in medical cannabis therapy
Known for thousands of years as a plant with healing properties, medical cannabis today plays an important role in the adjuvant therapy of various diseases. More than five decades of intensive investigation of the individual components of this plant by researchers in the fields of chemistry, pharmacology and medicine have led to groundbreaking scientific findings that are now finding their way into therapy with medical cannabis.
Fette Pharma's exclusive cooperation with the pharmaceutical company Cannbit from Israel guarantees a new level in medical cannabis therapy. Thanks to Cannbit's long-standing research lead, Fette Pharma has a large pool of valid clinical study data and scientific findings at its disposal for the development of its own preparations.
Find out more
More than 16 years of experience in medical cannabis research
Thanks to the cooperation of Fette Pharma with Cannbit, it is possible to use the more than 16-year research lead of the Israeli partner company Cannbit also in Germany. The RE:CANNIS preparations are based on valid clinical study data and therapy experience with more than 40,000 patients, which are documented in scientific publications, and represent their genetic advancements.
Find out more
More than 35 clinical and preclinical studies, more than 20 publications in leading scientific media
RE:CANNIS products are based on extensive therapeutic experience and their efficacy in various indications has been proven in numerous clinical and preclinical studies as well as in scientific publications.
Indications for medical cannabis therapy documented in studies include chronic pain syndrome, fibromyalgia, oncological diseases, Crohn's disease, ulcerative colitis, dementia, Parkinson's disease, Tourette's syndrome, epilepsy, and autism spectrum disorders.
Find out more
More than 40,000 patient data for the further development of therapy options
The long-standing research lead of the partner company Cannbit in Israel enables Fette Pharma to use the therapy experience based on more than 40,000 patient data for the development of its own preparations. Thanks to a large pool of valid clinical study data and scientific findings, as well as the ongoing research into new possible combinations of different cannabinoids in coordinated proportions, therapy options may open up for further clinical pictures and symptoms.
Find out more
